Evidence map›Paper›PMID 35619161›Full record

ArticleStem cell research & therapy2022

Knockdown of the stem cell marker Musashi-1 inhibits endometrial cancer growth and sensitizes cells to radiation.

Isabel Falke, Fabian M Troschel, Heike Palenta, Maria T Löblein, Kathrin Brüggemann, Katrin Borrmann, Hans Theodor Eich, Martin Götte, Burkhard Greve

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Role of the RNA-binding protein family in gynecologic cancers.American journal of cancer research · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Isabel Falke *Department of Radiation Oncology, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.ORCID 0000-0001-7845-6284
Fabian M Troschel *Department of Radiation Oncology, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany. fabian.troschel@uni-muenster.de.ORCID 0000-0001-5066-6650
Heike PalentaDepartment of Gynecology and Obstetrics, University Hospital Münster, 48149, Münster, Germany.
Maria T LöbleinDepartment of Radiation Oncology, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Kathrin BrüggemannDepartment of Gynecology and Obstetrics, University Hospital Münster, 48149, Münster, Germany.
Katrin BorrmannDepartment of Radiation Oncology, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Hans Theodor EichDepartment of Radiation Oncology, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Martin Götte *Department of Gynecology and Obstetrics, University Hospital Münster, 48149, Münster, Germany.
Burkhard Greve *Department of Radiation Oncology, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
University Hospital Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEndometrial carcinoma is the most common gynecological cancer in Europe. Musashi-1 is known to be a key regulator of endometrial cancer stem cells and a negative prognostic marker. In the present study, we aimed to understand growth and gene expression patterns in endometrial carcinoma after Musashi-1 knockdown in vitro and in vivo. Changes in therapeutic resistance were also assessed.

methodsFirst, we performed analyses to understand Musashi-1 expression patterns using The Cancer Genome Atlas database. We then proceeded to assess effects of small interfering RNA-based Musashi-1 targeting in two endometrial carcinoma cell lines, Ishikawa and KLE. After quantifying baseline changes in cell metabolism, we used MTT tests to assess chemotherapy effects and colony formation assays to understand changes in radioresistance. For mechanistic study, we used quantitative polymerase chain reaction (qPCR) and western blotting of key Musashi-1 target genes and compared results to primary tissue database studies. Finally, xenograft experiments in a mouse model helped understand in vivo effects of Musashi-1 knockdown.

resultsMusashi-1 is aberrantly expressed in primary tumor tissues. In vitro, silencing of Musashi-1 resulted in a strong decline in cell proliferation and radioresistance, while chemoresistance remained unchanged. Loss of Musashi-1 led to downregulation of telomerase, DNA-dependent protein kinase, the Notch pathway and overexpression of cyclin-dependent kinase inhibitor p21, the latter of which we identified as a key mediator of Msi-1 knockdown-related anti-proliferative signaling. In vivo, the anti-proliferative effect was confirmed, with Msi-1 knockdown tumors being about 40% reduced in size.

conclusionsMusashi-1 knockdown resulted in a strong decrease in endometrial cancer proliferation and a loss of radioresistance, suggesting therapeutic potential.

Indexed as

Endometrial NeoplasmsAnimalsBiomarkersBlotting, WesternCell ProliferationFemaleHumansMiceStem CellsBiomarkersCancer stem cellEndometrial cancerMusashi-1ProliferationRadioresistance

Identifiers

PMID35619161
PMCPMC9137084
OpenAlexW4281559581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.